Search

Your search keyword '"Kochanowicz, Jan"' showing total 379 results
Start Over Author "Kochanowicz, Jan"
379 results on '"Kochanowicz, Jan"'

4. Expanding Role of Interleukin-1 Family Cytokines in Acute Ischemic Stroke.

Author

Matys, Paulina, Mirończuk, Anna, Starosz, Aleksandra, Grubczak, Kamil, Kochanowicz, Jan, Kułakowska, Alina, and Kapica-Topczewska, Katarzyna

Subjects
IMMUNOLOGY of inflammation, ISCHEMIC stroke, INTERLEUKIN-37, INTERLEUKIN-33, INTERLEUKIN-1
Abstract

Ischemic stroke (IS) is a critical medical condition that results in significant neurological deficits and tissue damage, affecting millions worldwide. Currently, there is a significant lack of reliable tools for assessing and predicting IS outcomes. The inflammatory response following IS may exacerbate tissue injury or provide neuroprotection. This review sought to summarize current knowledge on the IL-1 family's involvement in IS, which includes pro-inflammatory molecules, such as IL-1α, IL-1β, IL-18, and IL-36, as well as anti-inflammatory molecules, like IL-1Ra, IL-33, IL-36A, IL-37, and IL-38. The balance between these opposing inflammatory processes may serve as a biomarker for determining patient outcomes and recovery paths. Treatments targeting these cytokines or their receptors show promise, but more comprehensive research is essential to clarify their precise roles in IS development and progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. 20S constitutive proteasome, 20S immunoproteasome, and cathepsin S are high‐sensitivity and independent markers of immunological activity in relapsing‐remitting type of multiple sclerosis.

Author

Górska, Ewelina, Tylicka, Marzena, Kamińska, Joanna, Hermanowicz, Adam, Matuszczak, Ewa, Ołdak, Łukasz, Gorodkiewicz, Ewa, Karpińska, Elżbieta, Socha, Katarzyna, Kochanowicz, Jan, Jakoniuk, Marta, Homšak, Evgenija, and Koper‐Lenkiewicz, Olga Martyna

Subjects
SURFACE plasmon resonance, MULTIPLE sclerosis, INFLAMMATION, SYMPTOMS, BIOSENSORS
Abstract

Research on the markers of autoimmune response in multiple sclerosis (MS) is still of great importance. The aim of our study was the evaluation of plasma 20S constitutive proteasome, 20S immunoproteasome, and cathepsin S concentrations as potential biomarkers of a relapsing‐remitting type of MS (RRMS). Surface plasmon resonance imaging (SPRI) biosensors were used for the evaluation of protein concentrations. Plasma 20S constitutive proteasome, 20S immunoproteasome, and cathepsin S concentrations were significantly higher in RRMS patients compared to the control group. All three parameters were characterized by excellent usefulness in differentiating MS patients from healthy individuals (AUC equal to or close to 1.000). The plasma concentration of analyzed parameters was not correlated with severity of disability in the course of RRMS (EDSS value), the number of years from the first MS symptoms, the number of years from MS diagnosis, or the number of relapses within the 24‐month observational period. Our study has shown that plasma concentrations of 20S constitutive proteasome, 20S immunoproteasome, and cathepsin S have promising potential in differentiating RRMS patients from healthy individuals. All of the analyzed parameters were found to be independent of the time of MS relapse and the severity of neurological symptoms. Hence, their potential as highly sensitive and independent circulating markers of RRMS suggests a stronger association with immunological activity (inflammatory processes) than with the severity of the disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Analysis of the Presence and Levels of IgG Antibodies Directed against the S1 Protein Receptor Binding Domain and the N Protein of SARS-CoV-2 in Patients with Multiple Sclerosis Treated with Immunomodulatory Therapies

Author

Kulikowska, Joanna, primary, Kapica-Topczewska, Katarzyna, additional, Gudowska-Sawczuk, Monika, additional, Kulczyńska-Przybik, Agnieszka, additional, Bazylewicz, Marcin, additional, Mirończuk, Anna, additional, Czarnowska, Agata, additional, Brola, Waldemar, additional, Mroczko, Barbara, additional, Kochanowicz, Jan, additional, and Kułakowska, Alina, additional

Published
2024
Full Text
View/download PDF

14. Genetic Update and Treatment for Dystonia.

Author

Koptielow, Jan, Szyłak, Emilia, Szewczyk-Roszczenko, Olga, Roszczenko, Piotr, Kochanowicz, Jan, Kułakowska, Alina, and Chorąży, Monika

Subjects
DYSTONIA, FOCAL dystonia, NEUROLOGICAL disorders, PARKINSON'S disease, ETIOLOGY of diseases, DEEP brain stimulation, SUBTHALAMIC nucleus
Abstract

A neurological condition called dystonia results in abnormal, uncontrollable postures or movements because of sporadic or continuous muscular spasms. Several varieties of dystonia can impact people of all ages, leading to severe impairment and a decreased standard of living. The discovery of genes causing variations of single or mixed dystonia has improved our understanding of the disease's etiology. Genetic dystonias are linked to several genes, including pathogenic variations of VPS16, TOR1A, THAP1, GNAL, and ANO3. Diagnosis of dystonia is primarily based on clinical symptoms, which can be challenging due to overlapping symptoms with other neurological conditions, such as Parkinson's disease. This review aims to summarize recent advances in the genetic origins and management of focal dystonia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis—A Systematic Review.

Author

Grunwald, Cezary, Krętowska-Grunwald, Anna, Adamska-Patruno, Edyta, Kochanowicz, Jan, Kułakowska, Alina, and Chorąży, Monika

Subjects
MULTIPLE sclerosis, INTERLEUKINS, NATALIZUMAB, AUTOIMMUNITY, INTERLEUKIN receptors, INTERLEUKIN-33, CENTRAL nervous system
Abstract

Multiple sclerosis is a disabling inflammatory disorder of the central nervous system characterized by demyelination and neurodegeneration. Given that multiple sclerosis remains an incurable disease, the management of MS predominantly focuses on reducing relapses and decelerating the progression of both physical and cognitive decline. The continuous autoimmune process modulated by cytokines seems to be a vital contributing factor to the development and relapse of multiple sclerosis. This review sought to summarize the role of selected interleukins in the pathogenesis and advancement of MS. Patients with MS in the active disease phase seem to exhibit an increased serum level of IL-2, IL-4, IL-6, IL-13, IL-17, IL-21, IL-22 and IL-33 compared to healthy controls and patients in remission, while IL-10 appears to have a beneficial impact in preventing the progression of the disease. Despite being usually associated with proinflammatory activity, several studies have additionally recognized a neuroprotective role of IL-13, IL-22 and IL-33. Moreover, selected gene polymorphisms of IL-2R, IL-4, IL-6, IL-13 and IL-22 were identified as a possible risk factor related to MS development. Treatment strategies of multiple sclerosis that either target or utilize these cytokines seem rather promising, but more comprehensive research is necessary to gain a clearer understanding of how these cytokines precisely affect MS development and progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies

Author

Kulikowska, Joanna, primary, Czarnowska, Agata, additional, Gudowska-Sawczuk, Monika, additional, Kulczyńska-Przybik, Agnieszka, additional, Bazylewicz, Marcin, additional, Collins, Francois, additional, Chorąży, Monika, additional, Mroczko, Barbara, additional, Kochanowicz, Jan, additional, Kapica-Topczewska, Katarzyna, additional, and Kułakowska, Alina, additional

Published
2022
Full Text
View/download PDF

28. Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL.

Author

Mojsak, Małgorzata, Szumowski, Piotr, Amelian, Anna, Hladunski, Marcin, Kubas, Bożena, Myśliwiec, Janusz, Kochanowicz, Jan, and Moniuszko, Marcin

Subjects
RADICAL prostatectomy, MAGNETIC resonance imaging, CANCER relapse, SURGICAL complications, RISK assessment, POSITRON emission tomography, DESCRIPTIVE statistics, RESEARCH funding, SENSITIVITY & specificity (Statistics), PROSTATE tumors, LONGITUDINAL method, DISEASE risk factors
Abstract

Simple Summary: PSMA PET is a relatively new method of molecular imaging in patients with prostate cancer, but in just a few years it has become the basic tool and standard of diagnosis in patients qualified for radical treatment as well as in biochemical recurrence. New data regarding new PSMA ligands labeled with various radioisotopes are constantly being reported. One should also not forget about the potential benefits of PET/MR prostate cancer diagnosis. The aim of the study was to assess the potential role of 18F-PSMA-1007 PET/MR in the diagnosis of patients with biochemical recurrence of prostate cancer. The use of 18F-PSMA-1007 and the role of PET/MR in the diagnosis of prostate cancer are not conclusively confirmed. There are reports indicating the potential pros and cons of using 18F-PSMA-1007 as well as the PET/MR technique in prostate cancer recurrence, but they are not yet included in the EAU guidelines. The aim of the study was to assess the effectiveness of 18F-PSMA-1007 PET/MR in detecting BCR lesions at very low PSA levels <0.5 ng/mL. Methods: Sixty patients with BCR after radical prostatectomy (RP) with PSA ranged 0.1–0.5 ng/mL were enrolled in a prospective study. All patients underwent simultaneous whole-body and pelvic 18F-PSMA-1007 PET/MR. The obtained results were verified by 12-month follow-up. Results: Fifty-three lesions were detected in 45 patients with 75% detection rate. The mean PSA value was 0.31 ng/mL. Of all PSMA-positive foci, 91% were localized in the pelvis, and only 9% of lesions were located in the extrapelvic region. Local recurrences were detected in 29%, PSMA-positive lymph nodes were detected in 64% of patients and bone metastases lesions were detected in 7% of patients. Conclusions: 18F-PSMA-1007 PET/MR seems to be an excellent diagnostic tool in patients with early BCR with very low PSA levels, especially with dt PSA < 6 months. The synergistic effect of combining 18F-PSMA-1007 and whole-body PET/MR with precise multiparametric assessment of pelvic lesions is of particular benefit in early BCR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland

Author

Czarnowska, Agata, primary, Tarasiuk, Joanna, additional, Zajkowska, Olga, additional, Wnuk, Marcin, additional, Marona, Monika, additional, Nowak, Klaudia, additional, Słowik, Agnieszka, additional, Jamroz-Wiśniewska, Anna, additional, Rejdak, Konrad, additional, Lech, Beata, additional, Popiel, Małgorzata, additional, Rościszewska-Żukowska, Iwona, additional, Perenc, Adam, additional, Bartosik-Psujek, Halina, additional, Świderek-Matysiak, Mariola, additional, Siger, Małgorzata, additional, Ciach, Agnieszka, additional, Walczak, Agata, additional, Jurewicz, Anna, additional, Stasiołek, Mariusz, additional, Kania, Karolina, additional, Dyczkowska, Klara, additional, Kalinowska-Łyszczarz, Alicja, additional, Galus, Weronika, additional, Walawska-Hrycek, Anna, additional, Krzystanek, Ewa, additional, Chojdak-Łukasiewicz, Justyna, additional, Ubysz, Jakub, additional, Pokryszko-Dragan, Anna, additional, Kapica-Topczewska, Katarzyna, additional, Chorąży, Monika, additional, Bazylewicz, Marcin, additional, Mirończuk, Anna, additional, Kulikowska, Joanna, additional, Kochanowicz, Jan, additional, Białek, Marta, additional, Stolarz, Małgorzata, additional, Kubicka-Bączyk, Katarzyna, additional, Niedziela, Natalia, additional, Warmus, Paweł, additional, Adamczyk-Sowa, Monika, additional, Podlecka-Piçtowska, Aleksandra, additional, Nojszewska, Monika, additional, Zakrzewska-Pniewska, Beata, additional, Jasińska, Elżbieta, additional, Zaborski, Jacek, additional, Milewska-Jȩdrzejczak, Marta, additional, Zwiernik, Jacek, additional, Zwiernik, Beata, additional, Potemkowski, Andrzej, additional, Brola, Waldemar, additional, and Kułakowska, Alina, additional

Published
2022
Full Text
View/download PDF

35. Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies

Author

Czarnowska, Agata, primary, Tarasiuk, Joanna, additional, Zajkowska, Olga, additional, Wnuk, Marcin, additional, Marona, Monika, additional, Nowak, Klaudia, additional, Słowik, Agnieszka, additional, Jamroz-Wiśniewska, Anna, additional, Rejdak, Konrad, additional, Lech, Beata, additional, Popiel, Małgorzata, additional, Rościszewska-Żukowska, Iwona, additional, Perenc, Adam, additional, Bartosik-Psujek, Halina, additional, Świderek-Matysiak, Mariola, additional, Siger, Małgorzata, additional, Ciach, Agnieszka, additional, Walczak, Agata, additional, Jurewicz, Anna, additional, Stasiołek, Mariusz, additional, Kania, Karolina, additional, Dyczkowska, Klara, additional, Kalinowska-Łyszczarz, Alicja, additional, Galus, Weronika, additional, Walawska-Hrycek, Anna, additional, Krzystanek, Ewa, additional, Chojdak-Łukasiewicz, Justyna, additional, Ubysz, Jakub, additional, Pokryszko-Dragan, Anna, additional, Kapica-Topczewska, Katarzyna, additional, Chorąży, Monika, additional, Bazylewicz, Marcin, additional, Mirończuk, Anna, additional, Kulikowska, Joanna, additional, Kochanowicz, Jan, additional, Białek, Marta, additional, Stolarz, Małgorzata, additional, Kubicka-Bączyk, Katarzyna, additional, Niedziela, Natalia, additional, Morawiec, Natalia, additional, Adamczyk-Sowa, Monika, additional, Podlecka-Piętowska, Aleksandra, additional, Nojszewska, Monika, additional, Zakrzewska-Pniewska, Beata, additional, Jasińska, Elżbieta, additional, Zaborski, Jacek, additional, Milewska-Jędrzejczak, Marta, additional, Zwiernik, Jacek, additional, Zwiernik, Beata, additional, Potemkowski, Andrzej, additional, Brola, Waldemar, additional, and Kułakowska, Alina, additional

Published
2022
Full Text
View/download PDF

43. Long-term adjunctive lacosamide treatment in patients with partial-onset seizures

Author

Rosenow, F., Kelemen, A., Ben-Menachem, E., McShea, C., Isojarvi, J., Doty, P., Berkovic, Sam, Kiley, Michelle, OʼBrien, Terence, Reutens, David Charles, Seneviratne, Wijesekera Udaya, Robinson, Martin Kevin, Schapel, Graham John, Somerville, Ernest Robertson, Babic, Tomislav, Poljakovic, Zdravka, Demarin, Vida, Hajnsek, Sanja, Bar, Michal, Buresova, Jindriska, Hojdikova, Helena, Kralove, Hradec, Marusic, Petr, Nespor, Evzen, Rektor, Ivan, Vacovska, Hana, Zarubova, Jana, Kälviäinen, Reetta K, Keränen, Tapani, Korpelainen, Juha Tapani, Lamusuo, Salla Liisi Kaarina, Nylund, Tuula, Crespel, Arielle, Derambure, Philippe, Ryvlin, Philippe, Semah, Franck, Tibergé, Michel, Valton, Luc, Arnold, Stephan, Siebold, Christoph, Holtkamp, Martin, Schmitz, Bettina, Lerche, Holger, Meencke, Heinz-Joachim, Nitsche, Michael, Tergau, Frithjof, Stefan, Hermann, Balogh, Attila, Halász, Péter, Horvath, Agnes, Komoly, Sámuel, Kondakor, István, Sólyom, András, Vécsei, László, Endziniene, Milda, Liesiene, Vanda, Mameniskiene, Ruta, Skaringa, Aloyzas Algimantas, Czlonkowska, Anna, Fryze, Waldemar, Kochanowicz, Jan, Mazurkiewicz-Beldzinska, Maria, Motyl, Rafal, Fedin, Anatoly, Guekht, Alla, Guzeva, Valentina, Karlov, Vladimir, Kotov, Sergey, Petrukhin, Andrey, Skoromets, Alexander, Gil-Nagel, Antonio, Llerda, Jose Angel Mauri, Moro, Mercedes Martin, Molins, Albert, Sanchez, Juan Carlos, Serratosa, M, Lindström, Per, Söderfeldt, Birgitta, Brodie, J, Cockerell, Oliver Charles, Cooper, Paul Nicholas, Roberts, Richard Charles, Sawhney, Inder Mohan Singh, and Smith, E M

Published
2016
Full Text
View/download PDF

44. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.

Author

Kulikowska, Joanna, Czarnowska, Agata, Gudowska-Sawczuk, Monika, Kulczyńska-Przybik, Agnieszka, Bazylewicz, Marcin, Collins, Francois, Chorąży, Monika, Mroczko, Barbara, Kochanowicz, Jan, Kapica-Topczewska, Katarzyna, and Kułakowska, Alina

Abstract

Clinical rationale for the study. The course of COVID-19 in people with multiple sclerosis (PwMS) has been described, while the serological status after SARS-CoV-2 infection or vaccination, especially in patients treated with disease-modifying therapies (DMT), is still under investigation. This is a significant clinical problem, as certain DMTs may predispose to a severe course of viral infections. Aim of the study. We analyzed the presence of antibodies against spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 in relapsing-remitting PwMS treated with DMT, especially dimethyl fumarate, interferon beta, and glatiramer acetate, in a single multiple sclerosis (MS) centre in north-eastern Poland (the Department of Neurology, Medical University of Bialystok). Material and methods. The presence of antibodies against S and N proteins in PwMS was assessed twice: on visit one (between May and June 2020) (n = 186) and on visit two (between May and June 2021) (n = 88). Samples were taken from 68 individuals on both visits. Demographic and clinical data was collected: duration of MS, Expanded Disability Status Scale Score (EDSS), type of DMT, history of COVID-19 (positive PCR or antigen test in the past), vaccination status, and the type of vaccine. Results. It was shown that on visit one: 3.7% (n = 7) PwMS were positive for IgA against S protein (IgA-S), 3.2% (n = 6) for IgG against S (IgG-S) protein, and none of those examined was positive for IgG against N protein (IgG-N). On visit two, the most common detected antibodies were IgG-S (71.3%; n = 62), then IgA-S (65.1%; n = 55), and the least common was IgG-N (18.2%; n = 16). On visit two: 20.45% of PwMS had a history of a positive SARS-CoV-2 PCR or antigen test during the last year. By the time of visit two, 42.05% (n = 37) of patients who participated in visit two had been full-course vaccinated against COVID-19. It was demonstrated that vaccination against SARS-CoV-2 significantly induces the production of IgG-S and IgA-S (p < 0.0001), while no difference between vaccinated and unvaccinated patients was shown in the detection of IgG-N. There was no correlation between COVID-19 infection and antibodies against proteins S and N in the study group. Moreover, the presented study did not show any relationship between the ability to produce antibodies against the S protein with any of the used DMTs. Conclusions and clinical implications. According to our study, PwMS treated with dimethyl fumarate, interferon beta, or glatiramer acetate can efficiently produce antibodies against SARS-CoV-2 both after infection and after vaccination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Plasmid Mediated mcr-1.1 Colistin-Resistance in Clinical Extraintestinal Escherichia coli Strains Isolated in Poland

Author

Majewski, Piotr, primary, Gutowska, Anna, additional, Smith, David G. E., additional, Hauschild, Tomasz, additional, Majewska, Paulina, additional, Hryszko, Tomasz, additional, Gizycka, Dominika, additional, Kedra, Boguslaw, additional, Kochanowicz, Jan, additional, Glowiński, Jerzy, additional, Drewnowska, Justyna, additional, Swiecicka, Izabela, additional, Sacha, Pawel T., additional, Wieczorek, Piotr, additional, Iwaniuk, Dominika, additional, Sulewska, Anetta, additional, Charkiewicz, Radoslaw, additional, Makarewicz, Katarzyna, additional, Zebrowska, Agnieszka, additional, Czaban, Slawomir, additional, Radziwon, Piotr, additional, Niklinski, Jacek, additional, and Tryniszewska, Elzbieta A., additional

Published
2021
Full Text
View/download PDF

47. Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

Author

Czarnowska, Agata, primary, Kapica-Topczewska, Katarzyna, additional, Zajkowska, Olga, additional, Adamczyk-Sowa, Monika, additional, Kubicka-Bączyk, Katarzyna, additional, Niedziela, Natalia, additional, Warmus, Paweł, additional, Kalinowska-Łyszczarz, Alicja, additional, Kania, Karolina, additional, Słowik, Agnieszka, additional, Wnuk, Marcin, additional, Marona, Monika, additional, Nowak, Klaudia, additional, Bartosik-Psujek, Halina, additional, Lech, Beata, additional, Perenc, Adam, additional, Popiel, Małgorzata, additional, Kucharska-Lipowska, Marta, additional, Chorąży, Monika, additional, Tarasiuk, Joanna, additional, Mirończuk, Anna, additional, Kochanowicz, Jan, additional, Lasek-Bal, Anetta, additional, Puz, Przemysław, additional, Maciejowska, Katarzyna, additional, Wawrzyniak, Sławomir, additional, Niezgodzińska-Maciejek, Anna, additional, Pokryszko-Dragan, Anna, additional, Gruszka, Ewa, additional, Budrewicz, Sławomir, additional, Białek, Marta, additional, Zwiernik, Jacek, additional, Michałowska, Anna, additional, Nosek, Krzysztof, additional, Zwiernik, Beata, additional, Lewańczyk, Bożena, additional, Brola, Waldemar, additional, and Kułakowska, Alina, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results